NCI Trials for May

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase 1 – 10187

A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma

National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128

Phase II – EA9171

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572

Phase II – NRG-GU006

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer

NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183

Phase III – CCTG MA.39

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711

Phase Other – ANBL17B5-Q

Growth Factor Receptor Trafficking and Neuroblastoma Differentiation

Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494


President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”